NEW YORK (GenomeWeb) – Vermillion and Quest Diagnostics have agreed to extend and amend their commercialization and services agreement for Vermillion’s OVA1 ovarian cancer test.
In a March 7, 2017 filing with the US Securities and Exchange Commission, Vermillion said it had amended the agreement to extend the initial term from March 11, 2017 to March 11, 2018 while also providing an option for an additional one-year renewal.
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?